SAB Biotherapeutics (NASDAQ:SABS) Announces Earnings Results

SAB Biotherapeutics (NASDAQ:SABS) announced its earnings results on Tuesday. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SABBio said SAFEGUARD enrollment is on track, with Part A fully enrolled and Part B now actively enrolling across the U.S., Australia, New Zealand, the U.K. and Europe.
• The company received FDA written confirmation that C-peptide may be used as a surrogate endpoint for accelerated approval, which management described as a meaningful de-risking of the regulatory path.
• Phase I SAB-142 data continued to support the program, with management highlighting beta-cell preservation, T-cell exhaustion, and a favorable safety profile including no serum sickness and low or no immunogenicity.
• SABBio ended Q1 with $217.6 million in cash, cash equivalents and available-for-sale securities, which it says funds operations through 2028 and supports SAFEGUARD plus pre-commercial work.
• The company also signed a multi-year manufacturing agreement with Emergent BioSolutions to support process development and both clinical and commercial production ahead of a potential launch.

SAB Biotherapeutics Trading Down 1.7%

Shares of SABS traded down $0.07 during trading hours on Tuesday, reaching $3.66. The stock had a trading volume of 359,968 shares, compared to its average volume of 645,977. SAB Biotherapeutics has a 52 week low of $1.60 and a 52 week high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02. The company has a market cap of $186.22 million, a P/E ratio of -1.58 and a beta of 0.55. The firm has a 50-day moving average of $3.87 and a 200 day moving average of $3.81.

Analyst Upgrades and Downgrades

SABS has been the subject of a number of research reports. Chardan Capital increased their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Zacks Research cut SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new stake in shares of SAB Biotherapeutics during the third quarter worth $32,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $30,000. Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $40,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics in the 3rd quarter worth $8,847,000. Finally, Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the 3rd quarter worth $22,954,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.